Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 258Breast Neoplasms 218Lung Neoplasms 207Glioblastoma 202Head and Neck Neoplasms 193Prostatic Neoplasms 179Squamous Cell Carcinoma of Head and Neck 171Lymphoma 152Rectal Neoplasms 139Esophageal Neoplasms 125Central Nervous System Neoplasms 122Leukemia 111Brain Neoplasms 107Pancreatic Neoplasms 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Gliosarcoma 87Esophageal Squamous Cell Carcinoma 84Sarcoma 82Uterine Cervical Neoplasms 81Neoplasms 81Lymphoma, Follicular 81Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Non-Hodgkin 75Hodgkin Disease 74Glioma 68Burkitt Lymphoma 67Colorectal Neoplasms 66Leukemia, Lymphocytic, Chronic, B-Cell 63Astrocytoma 63Neoplasm Metastasis 60

Interventions

Cyclophosphamide 14Dexamethasone 13Vincristine 11Cytarabine 11Methotrexate 9venetoclax 7Inotuzumab Ozogamicin 7Doxorubicin 7pegaspargase 6merphos 6blinatumomab 6Prednisone 6dexamethasone acetate 5dexamethasone 21-phosphate 5Mercaptopurine 5Calcium Dobesilate 5prednylidene 4deltacortene 4azathiopurine 4auricularum 4Specimen Handling 4Leucovorin 4Asparaginase 4Thioguanine 3Rituximab 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Methylprednisolone 3fludarabine 2calaspargase pegol 2asparaginase erwinia chrysanthemi recombinant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Radiotherapy × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡